VANCOUVER, British Columbia,
March 10, 2015 /PRNewswire/ -- InMed Pharmaceuticals
Inc. ("InMed") (CSE: IN; OTCQB: IMLFF) announces
it has formed an exclusive strategic collaboration with the
University of Debrecen, Hungary,
to develop novel phytocannabinoid-based therapies to treat ocular
allergic symptoms. The collaboration will leverage InMed's
proprietary Intelligent Cannabinoid Drug Design Platform (IDP) and
will be led by one of the world's leading cannabinoid researchers,
Dr. Tamas Biro, MD, PhD, DSc.
Dr. Biro has extensive research experience in studying the
endocannabinoid system (ECS) and the closely related transient
receptor potential (TRP) channels in various human diseases.
Under the discovery and development collaboration InMed's IDP
Platform will be used to identify cannabinoid- and
non-cannabinoid-based phytochemicals for ocular therapies focused
on reducing various pro-inflammatory cytokines in in vitro
and in vivo models.
Dr. Sazzad Hossain, Chief
Scientific Officer of InMed, stated, "We have accumulated
significant experience and expertise in developing cannabinoids to
treat ocular disease, which forms the basis of this strategic
collaboration. As we prepare to initiate Phase 1 clinical
trials of our lead phytocannabinoid-based drug candidate CTI-085
for glaucoma, we look forward to expanding our ophthalmic therapy
pipeline by developing ocular anti-allergic drugs, where we expect
Dr. Biro's 18 years of experience in this specialty field to be
invaluable."
"The global ocular allergy space is a multi-billion dollar
market and our platform offers a novel approach to potentially
treating a wide array of allergies," said Craig Schneider, President and CEO of
InMed. "We are excited to move a lead candidate toward
preclinical and clinical trials and will provide additional updates
as they become available."
About InMed
InMed is a clinical stage biopharmaceutical company that
specializes in developing cannabis-based therapies through the
research and development into the extensive pharmacology of
cannabinoids coupled with innovative drug delivery systems. InMeds'
proprietary platform technology, product pipeline and accelerated
development pathway are the fundamental value drivers of the
Company.
For more information, visit www.inmedpharma.com
ON BEHALF OF THE BOARD
InMed Pharmaceuticals Inc.
Craig Schneider
President and Chief Executive Officer
Tel: 604.669.7207
Fax: 604.683.2506
info@inmedpharma.com /
www.inmedpharma.com
Contact:
InMed Pharmaceuticals Inc.
Craig Schneider
President and Chief Executive Officer
T: 604.669.7207
F: 604.683.2506
E: info@inmedpharma.com
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
jdrumm@tiberend.com
212-375-2664
Amy Wheeler (Media)
awheeler@tiberend.com
646-362-5750
Forward Looking Statements
This news release may contain forward-looking statements and
information based on current expectations. These statements
should not be read as guarantees of future performance or results.
Such statements involve known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements to be materially different from those implied by such
statements. Although such statements are based on management's
reasonable assumptions, there can be no assurance that such
assumptions will prove to be correct. We assume no
responsibility to update or revise them to reflect new events or
circumstances.
Additionally, there are known and unknown risk factors which
could cause InMed Pharmaceuticals actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed Pharmaceuticals
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
These risks and uncertainties include, among others, the
possibility that clinical trials will not be successful, or be
completed, or confirm earlier clinical trial results, risks
associated with obtaining funding from third parties, risks related
to the timing and costs of clinical trials and the receipt of
regulatory approvals
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS
SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/inmed-forms-strategic-collaboration-to-develop-novel-phytocannabinoid-therapies-for-ocular-allergies-300048040.html
SOURCE InMed Pharmaceuticals Inc.